ArQule to Report Third Quarter 2013 Financial Results on November 7, 2013

  ArQule to Report Third Quarter 2013 Financial Results on November 7, 2013

Business Wire

WOBURN, Mass. -- October 31, 2013

ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its financial
results for the third quarter of 2013 on Thursday, November 7, 2013 at 7:00
a.m. Eastern Time. The Company will hold a conference call at 9:00 a.m.
Eastern Time that day to discuss these results.

Conference Call and Webcast
Date:                       Thursday, November 7, 2013
Time:                             9:00 a.m., Eastern Time

Conference Call Numbers
Domestic (toll free):             (877) 868-1831
International:                    (914) 495-8595

A replay of the conference call will be available beginning two hours after
the completion of the call through November 9, 2013 and can be accessed by
dialing toll-free 855-859-2056 or 800-585-8367 and from outside the U.S.
404-537-3406. The confirmation code for replayed calls is 86068331.

About ArQule

ArQule is a biotechnology company engaged in the research and development of
next-generation, small-molecule cancer therapeutics. The Company’s targeted,
broad-spectrum products and research programs are focused on key biological
processes that are central to human cancers. ArQule’s lead product, in Phase 2
and Phase 3 clinical development, is tivantinib (ARQ 197), an oral, selective
inhibitor of the c-MET receptor tyrosine kinase. The Company’s pipeline
includes: ARQ 092, designed to inhibit the AKT serine/threonine kinase, and
ARQ 087, designed to inhibit fibroblast growth factor receptor (FGFR).
ArQule’s current discovery efforts, which are based on the ArQule Kinase
Inhibitor Platform (AKIP™), are focused on the identification of novel kinase
inhibitors that are potent, selective and do not compete with ATP (adenosine
triphosphate) for binding to the kinase.


ArQule, Inc.
William B. Boni, 781-994-0300
VP, Investor Relations/
Corp. Communications
Press spacebar to pause and continue. Press esc to stop.